The group

History, from 2000 to 2010

> 2000: 

launch of the analgesic BIODALGIC Gé®.

> 2002: 

european orphan drug status granted for the antiepileptic DIACOMIT®.

> 2003: 

acquisition of the antidepressant MOCLAMINE®.

> 2005: 

acquisition of LOGIFLOX® and DECALOGIFLOX®, urinary antibiotics.

> 2006: 

creation of Offidis, a subsidiary intended for the market of dispensaries.

> 2007: 

european agreement granted for the antiepileptic DIACOMIT®.

> 2008: 

The setting up of 2 new subsidiaries abroad: one in Moscow (Russia), the other in Casablanca (Morocco).

Biocodex has been recognized for its therapeutic innovation in the pharmaceutical field and has been awarded the "Prix Galien" (The Galien Prize) for DIACOMIT.

Biocodex received the "Prix Empreintes 2008" (The Empreintes Prize) in the field of "General Practioner Prescribed Drugs" for the STRESAM advertising campaign.

The launch of OKIMUS for muscular cramp treatment.

> 2009: 

The launch of ARTISIAL (a saliva substitute).

Biocodex is committed to a sustainable development approach.

The OKIMUS advertising campaign was awarded the "Prix Empreintes 2009" (The Empreintes Prize) in the field of "Honorable Ethics of the year".

The opening of a new subsidiary in Istanbul (Turkey): this fifth subsidiary is part of the group"s strategic development abroad.

> 2010:

During the 13th Empreintes Prizes competition which rewards the best advertising innovations in the health field, Biocodex receives a special distinction for its campaign concerning the adjuvant treatment of muscle cramps.

2010 The opening of a secondary site at 2-6 avenue Gallieni, housing the Finance, Management Control, Pay and Purchasing departments

2010 The launch of DOLENIO, a primary therapy for arthritis belonging to the Symptomatic Slow-Acting Drugs For Osteoarthritis class (SYSADOA).